Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Health Catalyst (HCAT) Research & Development (2018 - 2025)

Health Catalyst (HCAT) has disclosed Research & Development for 8 consecutive years, with $12.4 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Research & Development changed N/A year-over-year to $12.4 million, compared with a TTM value of $59.4 million through Jun 2025, changed N/A, and an annual FY2022 reading of $75.7 million, up 20.64% over the prior year.
  • Research & Development was $12.4 million for Q2 2025 at Health Catalyst, down from $15.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $18.1 million in Q2 2022 and bottomed at $12.4 million in Q2 2025.
  • Average Research & Development over 5 years is $15.9 million, with a median of $16.4 million recorded in 2021.
  • The sharpest move saw Research & Development increased 24.95% in 2022, then decreased 19.66% in 2024.
  • Year by year, Research & Development stood at $17.5 million in 2021, then increased by 3.83% to $18.1 million in 2022, then decreased by 2.65% to $17.7 million in 2023, then fell by 19.66% to $14.2 million in 2024, then dropped by 12.69% to $12.4 million in 2025.
  • Business Quant data shows Research & Development for HCAT at $12.4 million in Q2 2025, $15.2 million in Q1 2025, and $14.2 million in Q3 2024.